Rocket Pharmaceuticals, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021. This is an annual filing; standalone fourth-quarter results are not provided. Rocket is a clinical-stage gene-therapy company developing treatments for rare diseases and has not generated product revenue.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $125.5 million | $105.4 million |
| General and administrative expense | $41.8 million | $28.9 million |
| Total operating expenses | $167.2 million | $134.3 million |
| Net loss | $169.1 million | $139.7 million |
| Net loss per share, basic and diluted | $2.67 | $2.52 |
| Cash used in operating activities | $121.2 million | $74.6 million |
| Cash, cash equivalents and investments at year-end | $388.7 million | $482.7 million |
Operating expenses increased 24.5%, with higher R&D spending reflecting manufacturing and development costs, increased headcount, and other program activity. G&A rose with stock compensation, staffing, insurance and commercial preparation. Net loss widened by $29.4 million. No meaningful operating margin is available because the company had no revenue.
At December 31, 2021, total assets were $497.0 million, total liabilities $42.3 million and stockholders’ equity $454.7 million. Cash and investments were $388.7 million, down from $482.7 million a year earlier. Management expected these resources to fund operating and capital expenditure needs into the second half of 2023. Operating cash use rose year over year; FY2021 investing activities provided $18.9 million, mainly reflecting investment maturities, and financing activities provided $37.7 million.
The 2021 and 2022 convertible notes were fully converted or redeemed during 2021; none remained outstanding at year-end. The balance sheet includes $20.8 million of finance-lease liabilities, primarily related to the Cranbury facility, and $1.8 million of operating-lease liabilities. The filing reports no material off-balance-sheet arrangements.
Business progress and material changes
- Danon disease (RP-A501): Phase 1 data showed early clinical activity in a small number of patients. One high-dose patient experienced complement-mediated thrombotic microangiopathy (TMA), acute kidney injury and progressive heart failure, later undergoing heart transplant. The FDA placed the study on clinical hold in May 2021 and lifted it in August after protocol changes. The company is focusing on the lower dose and will not administer the higher dose used in the study.
- Fanconi anemia (RP-L102): Interim Phase 1/2 results showed evidence of engraftment and MMC resistance in several patients. One patient’s influenza-associated marrow failure led to a successful allogeneic transplant. The company described the treatment as generally well tolerated without cytotoxic conditioning.
- LAD-I (RP-L201): Interim results showed CD18 expression above the reported survival-associated threshold in evaluable patients, with no product-related serious adverse events reported in the data described.
- PKD (RP-L301): Two adult patients had reported hemoglobin increases to normal levels, became transfusion independent, and showed improvements in hemolysis markers through 12 months. These are preliminary results from a small trial.
- Program prioritization: In December 2021 Rocket discontinued its sponsored clinical evaluation of RP-L401 for infantile malignant osteopetrosis and planned to return the program to academic innovators, focusing resources on RP-A501, RP-L102, RP-L201 and RP-L301.
Outlook, risks and unusual items
Management expects R&D expense to increase as programs advance and manufacturing capabilities develop. Rocket planned to begin GMP manufacturing at its Cranbury facility in 2022, while continuing to rely on third parties, including for LVV manufacturing. No product-launch, revenue or profitability guidance is provided.
- Key risks include clinical-trial safety and efficacy, small and difficult-to-enroll rare-disease populations, regulatory review, manufacturing execution, third-party supply dependence, reimbursement and the need for future capital. COVID-19 could disrupt enrollment, sites, supplies and regulatory activity.
- FY2021 included $12.8 million of non-cash R&D expense for warrants issued to a related party for business-development and asset-identification services. This included $7.6 million for an August warrant and $5.2 million for December warrants.
- In August 2021, a fund affiliated with largest shareholder RTW Investments purchased 812,516 shares for net proceeds of approximately $26.4 million. RTW beneficially owned approximately 25.2% of outstanding shares, according to the filing.
- Convertible-note conversions and the private placement contributed to dilution; shares outstanding rose to 64.5 million at year-end from 61.0 million a year earlier.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls. It identified accrued R&D expenses—approximately $12 million at year-end—as a critical audit matter because the estimates depend on services and milestones performed by CROs, manufacturers and trial sites.
Investor facts to verify
- Review full trial datasets, patient follow-up and regulatory requirements behind the preliminary results for all lead programs.
- Track RP-A501 safety, particularly complement-mediated TMA risk, the revised immunosuppression protocol and pediatric follow-up.
- Confirm whether RP-L102 engraftment and MMC-resistance results translate into durable clinical benefit and support the intended regulatory pathway.
- Monitor manufacturing readiness, clinical supply availability and the timing and cost of the Cranbury GMP facility buildout.
- Assess cash burn against management’s stated runway into the second half of 2023, including future financing needs and potential shareholder dilution.
- Examine the terms, valuation and governance implications of related-party warrants and the RTW private placement.